Five Hematology Drug Launches To Look Out For In 2022

In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are five new hematology products that could make their market debuts (or return) next year.  

3-D Rendering Red Blood Cells
• Source: Shutterstock

Sanofi’s hemophilia A therapy BIVV-001 (efanesoctocog alfa) is set to present a challenge to Roche Holding AG/Genentech, Inc. ’s prophylaxis product Hemlibra (emicizumab) and could corner a sizeable chunk of the on-demand market for Factor VIII products if it surmounts its final clinical and regulatory hurdles.

The product has a US fast-track designation, and assuming positive results in the Phase III XTEND-1 trial expected in January...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip